公开(公告)号：US20240352110A1

公开(公告)日：2024-10-24

申请号：US18745539

申请日：2024-06-17

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Alexander Jethwa ,  Tobias Oelschlaegel ,  Corinna Schindler ,  Monika Soukupova ,  Laura Stoeckl ,  Christina Zimmermann

IPC: C07K16/18 ,  G01N33/543 ,  G01N33/68

CPC classification number: C07K16/18 ,  G01N33/543 ,  G01N33/6896 ,  C07K2317/565 ,  G01N2333/4709 ,  G01N2470/04

Abstract: The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 with advantageous features for Aβ42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 as provided herein.

公开(公告)号：US20210199659A1

公开(公告)日：2021-07-01

申请号：US17186163

申请日：2021-02-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Sandra Rutz ,  David Morgenstern ,  Boris Pinchuk ,  Christina Zimmermann ,  Martin Klammer ,  Franziska Sonner

IPC: G01N33/573 ,  G01N33/574

Abstract: The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

公开(公告)号：US20210061924A1

公开(公告)日：2021-03-04

申请号：US17069349

申请日：2020-10-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: C07K16/40 ,  G01N33/543

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.

公开(公告)号：US20250043024A1

公开(公告)日：2025-02-06

申请号：US18772484

申请日：2024-07-15

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: C07K16/40 ,  G01N33/543

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1

公开(公告)号：US12077600B2

公开(公告)日：2024-09-03

申请号：US17069349

申请日：2020-10-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: G01N31/00 ,  C07K16/40 ,  G01N33/53 ,  G01N33/543

CPC classification number: C07K16/40 ,  G01N33/54326 ,  C07K2317/92

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.